Phase II study of epirubicin in advanced malignant melanoma |
| |
Authors: | Massimo Lopez Carlo-Federico Perno Paola Papaldo Luigi Di Lauro Fabrizio Ganzina Aldo Barduagni |
| |
Institution: | (1) Department of Medicine, National Cancer Institute Regina Elena, Rome, Italy;(2) Department of Therapeutic, Research, Farmitalia Carlo Erba, Milan, Italy;(3) Istituto Nazionale Tumori Regina Elena, Viale Regina Elena 291, 00161 Roma, Italy |
| |
Abstract: | Summary Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma. |
| |
Keywords: | malignant melanoma chemotherapy epirubicin |
本文献已被 SpringerLink 等数据库收录! |
|